Tests AGuIX nanoparticles with radiation for brain metastases
Tests whether AGuIX nanoparticles plus radiation help adults with brain cancer spread.
Key facts
- Who runs it
- Brigham and Women's Hospital
- Where
- Boston, United StatesSee the 2 sites
- Trial code
- Registry title
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 134 people, planned
- Started
- 15 Sept 2021
- Expected to end
- May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Stereotactic Radiation
- AGuIX gadolinium-based nanoparticles
- Placebo
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with brain metastases from a solid cancer that are harder to control with stereotactic radiation alone. They get radiation with AGuIX nanoparticles or with a placebo.
- Age
- 18 years or older at the time brain metastases were diagnosed.
- Sex
- All sexes can join.
- Disease stage
- Proven solid cancer with at least one brain metastasis of 5mm or more, plus one extra feature: melanoma growing despite immunotherapy, a gastrointestinal cancer, HER2-positive breast cancer, a cystic metastasis, a metastasis of 2cm (0.8 in) or more, or a metastasis that came back after earlier brain radiation.
- Earlier treatment
- Melanoma, gastrointestinal, HER2-positive breast, cystic or 2cm-or (0.8 in)-larger metastases that came back after earlier brain radiation can only join the groups that allow prior radiation. Anyone with prior brain radiation needs written approval from the study doctor.
- Biomarker or test result
- HER2-positive for the breast cancer group. Kidney function (estimated glomerular filtration rate) of at least 60 mL/min/1.73m2.
Main reasons for not taking part
- Cannot have a brain MRI or cannot receive gadolinium
- Widespread, definite leptomeningeal disease
- Needs radiation to more than 10 targets (more than 20 if whole brain radiation was given before)
- Pregnant or breastfeeding
- Karnofsky performance status below 70, or expected survival under 3 months from the cancer outside the brain
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Participants must have a biopsy proven solid malignancy and at least one intracranial measurable lesion spanning ≥5mm in maximal unidimensional size and radiographically consistent with or pathologically proven to be a brain metastasis AND meet one of the following additional criteria regarding the primary site or nature of the intracranial disease:; Melanoma with intracranial growth consistent with tumor progression despite immunotherapy; Gastrointestinal primary; HER2 positive breast cancer (subtype assessed using most representative tissue available in opinion of enrolling clinician and/or study PI); Cystic metastases; Metastases ≥2cm in maximal unidimensional size; Locally recurrent metastases after prior stereotactic radiation; Locally recurrent metastases after prior whole brain radiation *Patients with metastases from melanoma, GI primaries, or HER2+ breast cancer, as well as those with cystic metastases or metastases ≥2cm in maximal unidimensional size, who have local recurrences after prior brain-directed radiation can only be treated in the strata permitting prior radiation (last two strata above)
- Age ≥18 years at diagnosis of brain metastases
- Estimated glomerular filtration rate of ≥ 60 mL/min/1.73m2
- Karnofsky performance status of at least 70 (i.e. at minimum, "cares for self" but "unable to carry on normal activity or do active work")
- Estimated survival based on extracranial disease of at least 3 months in the opinion of the enrolling clinician and/or study PI
- Ability to understand and the willingness to sign a written informed consent document
- The effects of AGuIX on the developing human fetus are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of the therapeutic component of study participation
Who cannot take part
- Patients requiring radiation to either >10 targets (if naïve to whole brain radiation) or >20 targets (if whole brain radiation has been given previously) per the discretion of the treating clinician and/or study PI
- In cohorts who have received prior brain-directed radiation, patients are not eligible for this study if they have active (at the time of protocol screening) brain metastases that require radiation that are in or within 1.0cm of the brainstem, eyes, optic nerves, or optic chiasm if the juxtaposed organ at risk (i.e. brainstem, eyes, optic nerves, or optic chiasm) has previously received either >6.0 Gy in a single fraction or, if prior radiation was fractionated, a cumulative dose in 2.0 Gy equivalents, using an alpha/beta ratio of 2, of >40.0 Gy. In addition, all patients who have had prior brain-directed radiation, regardless of technique/dose/fractionation, are not eligible for the study until written approval is provided by the study/site PI
- Participants with widespread, definitive leptomeningeal disease
- Participants who cannot undergo a brain MRI
- Participants who cannot receive gadolinium
- Pregnant women are excluded from this study because of the potential deleterious effects of gadolinium on the developing fetus. Because there is an unknown but potential risk for adverse events in nursing infants, women who are breastfeeding are not eligible for this study
Where in United States
- Brigham and Women's HospitalBoston, United StatesContact: Ayal AizerTaking people
- Dana-Farber Cancer InstituteBoston, United StatesContact: Ayal Aizer, MD, MPHTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.
The 2 groups in the trial
- Stereotactic Radiation plus AGuIX gadolinium-based nanoparticlesTreatment being tested
Randomly assigned participants will receive: * AGuIX gadolinium-based nanoparticles 3-5 days before radiation is initiated * AGuIX gadolinium-based up to 2x during radiation, depending on standard of care radiation treatment. * If standard of care radiation treatment involves only one day of radiation, participant will receive AGuIX gadolinium-based nanoparticles on the day of radiation. * If standard of care radiation treatment involves 5 or 6 days of radiation, participant will receive AGuIX gadolinium-based nanoparticles two-times (2x) in total, on the first and third day of radiation.
Treatment: Stereotactic Radiation and AGuIX gadolinium-based nanoparticles
- Stereotactic Radiation plus placeboTreatment being tested
Randomly assigned participants will receive: * Placebo 3-5 days before radiation is initiated * Placebo up to 2x during radiation, depending on standard of care radiation treatment. * If standard of care radiation treatment involves only one day of radiation participant will receive Placebo on the day of radiation. * If standard of care radiation treatment involves 5 or 6 days of radiation participant will receive Placebo two-times (2x) in total, on the first and third day of radiation.
Treatment: Stereotactic Radiation and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone
- Plain-language title
- Tests AGuIX nanoparticles with radiation for brain metastasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 9 September 2026